In anticipation of targeted medicines, pharmaceutical and biotechnology companies are increasingly performing genetic studies of clinical trial participants in hopes of identifying genetic profiles that predict therapeutic outcomes. (sciencemag.org)
Research shows that clinical trial participants want to know if an investigator stands to profit from the outcome of a study, even though such disclosure not currently required. (scientificamerican.com)
These markers could be used to preselect clinical trial participants — and, eventually, patients — to those most likely to benefit from a new drug. (sciencemag.org)